Research Paper Volume 16, Issue 11 pp 9899—9917

Figure 11. Immunotherapy and drug sensitivity. Correlations between the risk score and immunophenoscore (IPS) for patients receiving anti-PD1 alone (A), patients receiving anti-CTLA4 alone (B), and patients receiving combined anti-PD1 and anti-CTLA4 treatments (C). The drug sensitivity to doxorubicin (D), talazoparib (E), palbociclib (F), phenformin (G), rapamycin (H), and Naviroclax (I).